Yiling Pharmaceuticals' new drug Qifeng Bitong Tablet for allergic rhinitis has been included in the national medical insurance.

The "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog" for 2025 was officially announced today in Guangzhou. A new type of drug, Qifang Bitong Tablets, independently developed by Ling Pharmaceutical, has been included in the national medical insurance catalog for the first time. It is reported that Qifang Bitong Tablets is an innovative traditional Chinese medicine specifically for the treatment of persistent allergic rhinitis, filling a gap in clinical medication. The drug was approved for market authorization by the National Medical Products Administration in January 2025 and received registration approval from the Macao Special Administrative Region Government Drug Administration on July 12, becoming the first innovative traditional Chinese medicine to be approved for registration in Macao.